Page URL:

Gene therapy shows promise at treating immunodeficiency

14 December 2015
Appeared in BioNews 832

Two patients enrolled in a clinical trial of a gene therapy to treat severe congenital immunodeficiency have shown signs of substantial improvements in their condition.

The study is being carried out by researchers working for the US National Institutes of Health to test the safety and effectiveness of gene therapy combined with low-dose chemotherapy in five patients aged seven to 24 affected by X-linked severe combined immunodeficiency (SCID-X1).

SCID-X1 is a rare condition caused by a mutation in the IL2RG gene, affecting the body's ability to produce several types of white blood cell. Those affected by the condition have little or no immune system and are highly susceptible to infectious diseases.

The existing treatment for SCID-X1 typically involves transplanting stem cells from a tissue-matched sibling or from the affected infant's parents, which can then develop into white blood cells. However, gene therapy would remove the need for a donor as the cells come from the patients themselves. It also reduces the risk of graft-versus-host disease (GVHD), where the transplanted immune cells ending up attacking the recipient's tissues.

The trial uses genetically engineered viruses to insert functional copies of the IL2RG gene into a patient's own stem cells, which are then reintroduced to allow them to develop into the various types of blood cell needed by the immune system. While this technique has been employed successfully in babies (see BioNews 775), this is the first report of it also appearing to work in older children and young adults.

Two of the five patients currently enrolled in the study, both of whom are in their 20s, are reported to be showing signs of long-term improvement. The researchers have observed a positive response to vaccinations and a reduction in some of their SCID symptoms, such as chronic warts and norovirus infections, suggesting an improvement in their immune status. The other three patients have only undergone the treatment within the last few months, making it too early to measure effectiveness.

However, the interim results are consistent with other similar studies and, should these results bear out, it could give hope to patients with this and similar genetic diseases.

The trial is being conducted by the National Institute of Allergy and Infectious Diseases, and the findings were presented at a conference of the American Society of Hematology.

6 March 2017 - by Ayala Ochert 
A teenage boy in France appears to have been cured of sickle cell disease using a gene therapy. He has been free of all signs of the disease for 15 months...
12 September 2016 - by Dr Nicoletta Charolidi 
A genetically engineered virus that triggers the production of an alternative form of haemoglobin has reversed the symptoms of sickle cell disease in mice...
11 April 2016 - by Rebecca Carr 
A gene therapy for children with a rare but life-threatening genetic disorder that severely weakens the immune system has been recommended for approval by the European Medicines Agency...
27 July 2015 - by Daniel Malynn 
In Great Ormond Street, we meet three families all facing rare genetic immune diseases. The documentary witnesses the utter anguish the families go through and the heartbreaking decisions parents have to make...
13 October 2014 - by Dr James Heather 
Gene therapy to treat children with 'bubble boy syndrome' seems to be both safe and effective, a study published in the New England Journal of Medicine has found...
16 December 2013 - by Dr Rachel Montgomery 
Gene therapy trials using engineered immune cells have shown considerable progress in treating blood disorders, according to findings presented at the American Society of Hematology's annual meeting...
17 December 2012 - by Joseph Jebelli 
A seven-year-old girl with a highly aggressive form of leukaemia may have been 'cured' by an experimental therapy that harnesses the body's immune system to seek out and destroy the disease....
5 November 2012 - by Dr Lucy Spain 
The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.